<h2>Can screening for T1D autoantibodies help prevent DKA?</h2>
Anti-islet autoantibodies, responsible for destruction of insulin-producing beta-cells, can be detected during the presymptomatic phase (Stage 1 and 2) of autoimmune T1D. If left undetected, there is progression from the presymptomatic phase to symptomatic phase (Stage 3), which is characterized by beta-cell functional loss and hyperglycemia, which may often lead to ketoacidosis.6
<h3>Stages of autoimmune type 1 diabetes6</h3>

Delay in screening for autoimmune type 1 diabetes (T1D) can increase the risk of diabetic ketoacidosis (DKA) at diagnosis—a critical complication that is potentially life-threatening and may result in long-term poor glycemic control and neurological complications.1,2 By identifying autoimmune T1D early, you can significantly lower the risk of DKA at diagnosis.3,4

TYPE-1-DIABETES

DIABETES

Early detection of autoimmune type 1 diabetes could reduce the risk of diabetic ketoacidosis

Know more about different stages of autoimmune T1D

Click here to know more about different stages of autoimmune T1D.
Screening for beta-cell autoantibodies in high-risk individuals allows for early diagnosis of T1D, timely intervention through monitoring and treatment, and prevention of complications such as DKA.1,6 Moreover, preventing DKA through screening results in reduced DKA-associated morbidity, mortality, and healthcare cost.4

<h3>Benefits of early T1D screening2,4</h3>

<h2>Is DKA a critical risk for children with T1D?</h2>
Diabetic ketoacidosis is a critical complication and the leading cause of hospitalization in children with autoimmune T1D. It accounts for 70% of diabetes-related deaths in those under 10 years, often due to cerebral edema.5,7&nbsp;
Type 1 diabetes is often diagnosed following a DKA event. The incidence of DKA at the onset of T1D varies worldwide, ranging from 15% to 80%.8 Diabetic ketoacidosis at the diagnosis of autoimmune T1D significantly worsens glycemic control by potentially accelerating beta-cell loss. Additionally, children who experience DKA may face long-term cognitive complications, impairing their ability to engage in self-care.2

<h2>Who is at risk of DKA?</h2>
Diabetic ketoacidosis predominantly affects people with T1D but can also occur in those with type 2 diabetes. Common triggers in both populations include catabolic stress from:9
<ul>
 <li>Acute illnesses and injuries</li>
 <li>Surgery</li>
 <li>Infections</li>
 <li>Non-compliance with treatment</li>
 <li>New-onset diabetes</li>
 <li>Other acute medical conditions</li>
</ul>
The risk of DKA is notably higher among younger children with T1D.1 It is concerning that T1D diagnosis in children under 5 years often coincides with DKA. The reported prevalence of DKA in this age group at diagnosis ranges from 17.3% to 54.5%.4 Recognizing signs and symptoms in these children can be particularly challenging, potentially leading to delayed diagnosis.1
<h3>Risk of DKA by age1</h3>

Children of siblings of individuals with T1D show the lowest rate of DKA, highlighting the importance of parental awareness regarding diabetes signs and symptoms.2

<h2>What is the pathogenesis of DKA?</h2>
Autoimmune T1D, resulting from the destruction of pancreatic beta-cells, causes insulin deficiency. Insulin deficiency, coupled with increased counterregulatory hormones, triggers the release of free fatty acids from adipose tissue. These fatty acids are then oxidized in the liver to form ketone bodies, leading to ketoacidosis. This ultimately causes worsening of hyperglycemia, as illustrated in the below figure.5,9
<h3>Pathogenesis of DKA10</h3>

<h2>How is DKA evaluated?</h2>
Diabetic ketoacidosis can be evaluated through both clinical signs and laboratory tests. Clinically, DKA manifests with symptoms such as polyuria, polydipsia, hyperglycemia, weight loss and acetone breath.11
<h3>Symptoms of DKA11</h3>

In addition to clinical signs, DKA is characterized by specific laboratory findings, with the presence of:5
<ul style="margin-top:8px; margin-bottom:8px">
 <li style="margin-top:8px; margin-bottom:8px; margin-left:8px">Hyperglycemia (blood glucose &gt;200 mg/dL),</li>
 <li style="margin-top:8px; margin-bottom:8px; margin-left:8px">Metabolic acidosis (venous pH &lt;7.3 or serum bicarbonate concentration 
 &lt;15 mEq/L), and </li>
 <li style="margin-top:8px; margin-bottom:8px; margin-left:8px">Ketonemia or moderate/high ketonuria</li>
</ul>
The severity of DKA is primarily determined by the degree of acidosis observed in these laboratory parameters, as depicted in below table.5 
<h3 style="margin-top: 8px; margin-bottom: 8px;">Diabetic ketoacidosis severity classification5</h3>
<table align="center" border="1" cellpadding="1" cellspacing="1" style="width:100%;">
 <tbody>
 <tr>
 <td style="background-color: rgb(112, 34, 221);">&nbsp;</td>
 <td style="background-color: rgb(112, 34, 221);">
 Mild</td>
 <td style="background-color: rgb(112, 34, 221);">Moderate</td>
 <td style="background-color: rgb(112, 34, 221);">Severe</td>
 </tr>
 <tr>
 <td>Serum pH</td>
 <td style="text-align: center;">7.2-7.3</td>
 <td style="text-align: center;">7.0-7.2</td>
 <td style="text-align: center;">&lt;7.0</td>
 </tr>
 <tr>
 <td style="border-bottom:1px solid black; width:204px; padding:0cm 7px 0cm 7px; height:25px; border-top:1px solid black; border-right:1px solid black; border-left:1px solid black">
 Serum HCO3 (mEq/L)</td>
 <td style="text-align: center;">15–18</td>
 <td style="text-align: center;">10–15</td>
 <td style="text-align: center;">&lt;10</td>
 </tr>
 </tbody>
</table>
HCO3, bicarbonate

DKA is a life-threatening condition often associated with high mortality, morbidity, and healthcare expenditure. Early screening and detection of T1D are crucial for preventing DKA1,5

References
<ol style="margin-top:8px; margin-bottom:8px">
 <li style="margin-top:8px; margin-bottom:8px; margin-left:8px">Cherubini V, Grimsmann JM, Åkesson K, et al. Temporal trends in diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes between 2006 and 2016: results from 13 countries in three continents. Diabetologia. 2020;63(8):1530-1541. </li>
 <li style="margin-top:8px; margin-bottom:8px; margin-left:8px">Duca LM, Wang B, Rewers M, and Rewers A. Diabetic ketoacidosis at diagnosis of type 1 diabetes predicts poor long-term glycemic control. Diabetes Care. 2017;40(9):1249-1255. </li>
 <li style="margin-top:8px; margin-bottom:8px; margin-left:8px">Nakhla M, Cuthbertson D, Becker DJ, et al. Diabetic ketoacidosis at the time of diagnosis of type 1 diabetes in children: insights from TRIGR. JAMA. 2021;175(5):518-520. </li>
 <li style="margin-top:8px; margin-bottom:8px; margin-left:8px">Elding Larsson H, Vehik K, et al. TEDDY Study Group; SEARCH Study Group; Swediabkids Study Group; DPV Study Group; Finnish Diabetes Registry Study Group. Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care. 2011;34(11):2347-2353.</li>
 <li style="margin-top:8px; margin-bottom:8px; margin-left:8px">Bonadio W. The evaluation and management of pediatric diabetic ketoacidosis: A comprehensive review. Clinical Pediatrics. 2024; 62 (6):551-564.</li>
 <li style="margin-top:8px; margin-bottom:8px; margin-left:8px">Sims EK, Besser REJ, Dayan C, et al; NIDDK type 1 diabetes TrialNet study group. Screening for type 1 diabetes in the general population: A status report and perspective. Diabetes. 2022;71(4):610-623.</li>
 <li style="margin-top:8px; margin-bottom:8px; margin-left:8px">Wolfsdorf J, Craig ME, Daneman D, et al. Diabetic ketoacidosis. Pediatric Diabetes. 2007;8(1):28-42.</li>
 <li style="margin-top:8px; margin-bottom:8px; margin-left:8px">Simmons KM and Sims EK. Screening and prevention of type 1 diabetes: Where are we? J Clin Endocrinol Metab. 2023;108(12):3067-3079.</li>
 <li style="margin-top:8px; margin-bottom:8px; margin-left:8px">Lizzo JM, Goyal A, and Gupta V. Adult diabetic ketoacidosis. [Updated 2023 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <a href="https://www.ncbi.nlm.nih.gov/books/NBK560723/" style="color:#0563c1; text-decoration:underline" target="_blank" title="https://www.ncbi.nlm.nih.gov/books/NBK560723/">https://www.ncbi.nlm.nih.gov/books/NBK560723/</a>. Accessed on 10 Jul 2024. </li>
 <li style="margin-top:8px; margin-bottom:8px; margin-left:8px">Algarni A. Treatment considerations and pharmacist collaborative care in diabetic ketoacidosis management. J Pharmacol Pharmacother. 2022;13(3):215–221.</li>
 <li style="margin-top:8px; margin-bottom:8px; margin-left:8px">Lee CS and Rickard J. Review of diabetic ketoacidosis management. USPharm. 2018;43(11):26-28.</li>
</ol>

Delay in screening for autoimmune type 1 diabetes (T1D) can increase the risk of diabetic ketoacidosis (DKA) at diagnosis—a critical complication that is potentially life-threatening and may result in long-term poor glycemic control and neurological complications.1,2 By identifying autoimmune T1D early, you can significantly lower the risk of DKA at diagnosis.3,4

To read the full content, activate your Sanofi Campus account. Please confirm your email address in the email you received.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

This information will only be used to validate your account and will not be distributed.

title

Before starting exploring, we can suggest you specific and relevant content

Title

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

To offer you a personalised experience, you must

Your profile is incomplete

The ADCT gives a measure of how controlled the eczema is. Answer these 6 simple questions with your patient to find the ADCT score. It will indicate proper course of action.

Atopic dermatitis, a type of eczema, may be affecting your Patient's life in more ways than you know.

Take the Atopic Dermatitis Control Test (ADCT)

Enjoy more exclusive content{newline}by <a>registering today</a>

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

This website is for US healthcare professionals only.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

We're usually a treasure chest of knowledge, but we couldn't find what you're looking for.

We were unable to find what you're searching for

Sanofi does not review or control the content of non-Sanofi websites. 
MAT-US-2405606-v1.0-06/2024

You are about to leave Campus.sanofi/uk.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

This site is intended for healthcare professionals and relevant for HCPs.  It contains information on Sanofi medicines, educational resources, and promotional contents.  By entering this site, you are confirming that you are a healthcare professional.  

MAT-US-2405606-v1.0-06/2024

Welcome to Sanofi Campus US

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privacy matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My consents

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please log in to access to the results

You need to sign-in to your account in order to access medical content.

Please Log In

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Latest Articles

Early detection of autoimmune type 1 diabetes could reduce the risk of diabetic ketoacidosis